CSL Says Cardiovascular Drug CSL112 Didn't Meet 'Efficacy Endpoint' After Study
By Mike Cherney
SYDNEY--Australia-based pharmaceutical company CSL said its Phase 3 study into whether its CSL112 drug reduced the risk of cardiovascular events after a heart attack "did not meet its primary efficacy endpoint."
CSL said there are no plans for a regulatory filing but that the study's results would continue to be analyzed over the coming months. It said the study, which involved more than 18,000 patients in dozens of countries, was the most ambitious study in the company's history.
The company said CSL had excluded any financial contribution from CSL112 in its forward-looking statements, and that it doesn't expect any material financial impact following the end of the study.
CSL said it will discuss CSL112 at its half-year result on Tuesday.
Write to Mike Cherney at mike.cherney@wsj.com
(END) Dow Jones Newswires
February 11, 2024 16:46 ET (21:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters